Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates

Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection —— Exercised 40% U.S. Profit-Share option for the HSV helicase primase inhibitor program —— Received first $75 million collaboration extension fee from Gilead; cash runway projected into 2029 —SO…